Quick Takeaways: Why It Matters? Presenting full SLAB trial data for GF‑1004 (a SIRT6‑based gene therapy) positions Genflow to seek an animal‑health licensing or co‑development deal in a fast‑growing pet longevity/sarcopenia niche. If the results show meaningful improvements in...
Quick Takeaways: Why It Matters? Gelteq’s canine palatability trials with Kemin confirm that its gel-based delivery platform can effectively mask bitter compounds and deliver strong acceptance across multiple flavor profiles, even with naturally unpalatable ingredients. This is a key enabl...
